Medical News Today: Scientists use stem cells to restore testosterone

Researchers have used stem cells to create testosterone-producing cells in rodents. This may provide an alternative to hormone replacement therapy.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Stem Cell Research Source Type: news

Related Links:

CONCLUSION:Our study using a clinically relevantin vitro model suggests that bisphosphonate treatment is more effective for patients with osteoporosis than its preventive effect for healthy person. In addition, patient-specific responses to bisphosphonates should be considered rather than bisphosphonate type prior to prescription. Further investigations are needed to determine how bisphosphonates influence hBMSCs function to mediate bone quality and turnover in osteoporotic patients. Such studies can generate novel approaches to treat age-related osteoporotic bone loss.
Source: Tissue Engineering and Regenerative Medicine - Category: Biotechnology Source Type: research
More than 100 women die of breast cancer in the U.S. every day. It's the second leading cause of cancer deaths in American women. But in my opinion, many of those women really die of a tragic medical error. Let me explain… Millions of women in the U.S. have taken Big Pharma's hormone replacement therapy (HRT). Their doctors prescribe it to try to relieve the symptoms of menopause. Like hot flashes, night sweats, mood swings and weight gain. But what the drug companies try to pass off as hormones are actually synthetic concoctions. They are fake versions of the estrogen and progesterone that your body makes ...
Source: Al Sears, MD Natural Remedies - Category: Complementary Medicine Authors: Tags: Anti-Aging Source Type: news
AbstractBackgroundFemale childhood cancer survivors who develop gonadal dysfunction require female hormone replacement therapy (HRT) from puberty until menopause. However, the support provided in such cases has not been studied. We investigated the physical and social characteristics and support needs of adult female childhood cancer survivors who underwent HRT.MethodsForty-nine adult female childhood cancer survivors completed self-administered questionnaires. We compared the clinical characteristics, health status, and social conditions between a group that underwent HRT and a group that did not, and we surveyed support ...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
This article highlights our own and current research on the induction of steroidogenic cells from various stem cells. We also discuss the future direction of their clinical application. PMID: 27681884 [PubMed - as supplied by publisher]
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
Conclusion: Progestins have mixed effects on breast cancer PDX tumor growth. Tumors that have high ER and PR and are highly estrogen-dependent are more likely to exhibit strong growth inhibition by progestins (both P4 and MPA). Tumors with mixed luminal/basal phenotype that have less ER and PR and are moderately estrogen-dependent are less likely to be progestin-inhibited. In tumors with low ER and PR but high AR content MPA can act as an AR agonist to stimulate growth. Tumor-specific downstream estrogen-dependent pathways such as Notch may indicate whether progestins are therapeutic. Additional tumors are needed to confir...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Luminal Breast Cancer: Poster Presentations - Proffered Abstracts Source Type: research
In this study, we tested the effects of luteolin, a flavonoid commonly found in fruits and vegetables, on proliferation of BT-474 and T47-D breast cancer cells and their P-dependent production of VEGF. Luteolin treatment (25-100 μM) for 24-48 h reduced in vitro tumor cell viability and induced apoptosis. Interestingly, treatment with a lower concentration of luteolin (10 μM) blocked the production of P-dependent VEGF, indicating that VEGF suppression precedes luteolin-mediated loss of cell viability. Furthermore, luteolin (20 mg/kg, i.p.) suppressed the growth of MPA-dependent T47-D human xenograft tumors in nude mic...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Publication date: Available online 25 January 2016 Source:Pharmacology & Therapeutics Author(s): Inthrani Raja Indran, Ryan Lim Zhen Liang, Tan Ee Min, Eu-Leong Yong The morbidity and mortality associated with fractures due to osteoporosis or “porous bone” contributes significantly to global healthcare costs and will increase exponentially with ageing populations. In menopausal women, the onset of menopause and rapid estrogen withdrawal leads to osteoporotic fractures. Healthy bone requires the coordinated remodelling function of osteoclasts, osteoblasts, osteocytes in the basic bone multicellular uni...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
This study provides a new mechanistic basis for progesterone and radiation-induced breast cancer risk. In addition, the elucidation of new pathways and miRNA regulations involved in CSC generation and maintenance may open the door to potential new strategies for basal cancer primary or adjuvant therapy, by blocking non-CSCs from replenishing the pool of CSCs and by targeting mechanisms responsible for CSC maintenance. Such CSC-focused therapies may be effective at preventing metastasis and relapse.Citation Format: Guillaume Vares, Sei Sai, Bing Wang, Akira Fujimori, Mitsuru Nenoi, Tetsuo Nakajima. Progesterone generates ca...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Tumor Biology Source Type: research
Combined hormone replacement therapy (HRT) containing progestins (P) and estrogens (E) has been shown to increase the risk of breast cancer in post-menopausal women (JNCI, 2000, 92:328). We showed that the commonly used P, medroxyprogesterone acetate (MPA), increases production of the potent angiogenic growth factor VEGF in breast cancer cells (Int J Cancer, 2001, 92:469). Furthermore, it has been established that P drives tumor progression in an in-vivo xenograft model (Can Res 2007; 67:9929). CD44 has recently been shown to be expressed by cancer stem cells (CSC) (Nature Reviews Cancer 2011; 11:254), and has therefore be...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Endocrinology Source Type: research
Clinical and epidemiological evidence show that combined estrogen (E) and progestin (P) hormone replacement therapy (HRT) increases the risk of breast cancer in postmenopausal women. Tumor progression is dependent on cell survival and angiogenesis, which provides nutrients vital to the developing cancer. We have shown that physiological levels of P (10 nM), including medroxyprogesterone acetate (MPA), which is widely used in HRT, increases the production of the potently angiogenic vascular endothelial growth factor (VEGF), in human breast cancer cells both in vitro and in vivo. The anti-progestin RU-486 blocks this effect,...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Tumor Biology Source Type: research
More News: Health | Hormone Replacement Therapy | Hormones | Stem Cell Therapy | Stem Cells